
The European Commission (EC) has granted orphan drug status for an immunosuppressant drug (Sirolimus, Santen Inc.) for the treatment of chronic non?infectious uveitis. The designation follows a positive opinion from the Committee for Orphan Medicinal Products within the European Medicines Agency in June.